関連する実験動画
Updated: Feb 28, 2026

07:03
Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration
Published on: May 4, 2017
72.4K
犬アレルゲンおよびエンドトキシンによる肺機能および喘息に対する保護効果
Makiko Nanishi1, Myrtha E Reyna2, Marija Pajdakovska1
1Division of Respiratory Medicine, Department of Pediatrics, Hospital for Sick Children & Research Institute, Toronto, Ontario, Canada.
The Journal of allergy and clinical immunology
|February 25, 2026
まとめ
乳児期の高レベルの犬アレルゲン(Can f1)への早期曝露は、5歳までに肺機能が改善し、喘息のリスクが低下することに関連していました。この保護効果は、肺機能の遺伝的素因スコアが低い子供でより顕著でした。
科学分野:
- 環境衛生
- 小児アレルギー
- 遺伝学
背景:
- 小児喘息は、特にアレルゲンとの複雑な遺伝子と環境の相互作用を伴います。
- アレルゲン曝露と喘息リスクに関する以前の研究では、一貫性のない結果が得られています。
研究 の 目的:
- 乳児期の室内アレルゲン曝露と、5歳時の喘息発症および肺機能との縦断的関連を調査すること。
- これらの関連を修飾する上での遺伝的要因の役割を探求すること。
主な方法:
- 生後3か月の乳児のダニサンプルを対象に、Can f1(犬アレルゲン)、Fel d1(猫アレルゲン)、およびエンドトキシンを測定しました。
- 5歳時に喘息診断およびスパイロメトリーを実施しました。
- 肺機能のポリジーンスコア(PGS)を使用して遺伝子と環境の相互作用を調べました。
主要な成果:
- 高レベルのCan f1曝露は、喘息のリスクを有意に低下させること(OR 0.52)と関連していました。
- 高レベルのCan f1曝露を有する子供は、喘息の有無にかかわらず、有意に改善したFEV1 zスコア(β=0.23)を示しました。
- Can f1曝露と肺機能のPGSとの間に有意な遺伝子と環境の相互作用が観察されました。
結論:
- 一般集団コホートにおける乳児期の高レベルのCan f1への早期曝露は、肺機能の改善および小児喘息に対する保護と関連しています。
- 高レベルのCan f1曝露は、遺伝的に感受性の高い個人(低PGSを有する者)の肺機能を特異的に調節する可能性があります。
関連する概念動画
Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Drugs Used in Lower Respiratory Disorders: Overview
1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Allergic Reactions
32.7K
Overview
32.7K

